Valuation : Gabather AB

Market Cap 20.63M 2.17M 1.86M 1.74M 1.6M 3.01M 207M 3.01M 8.07M 104M 8.14M 7.97M 345M P/E 2024
-1.07x
P/E 2025 -1.13x
Enterprise Value 17.49M 1.84M 1.58M 1.48M 1.35M 2.55M 176M 2.56M 6.84M 88.47M 6.9M 6.75M 293M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
90.95%
Yield 2024 *
-
Yield 2025 -
1 day-2.87%
1 week+3.05%
Current month+13.42%
1 month+9.74%
3 months-17.16%
6 months+5.62%
Current year+23.36%
1 week 0.03
Extreme 0.0304
0.04
1 month 0.03
Extreme 0.0262
0.04
Current year 0.02
Extreme 0.023
0.1
1 year 0.02
Extreme 0.023
0.1
3 years 0.02
Extreme 0.023
4.2
5 years 0.02
Extreme 0.023
6.55
10 years 0.02
Extreme 0.023
62.8
Manager TitleAgeSince
Chief Executive Officer - 2018-09-30
Chief Operating Officer - 2017-12-31
Chief Tech/Sci/R&D Officer - 2017-12-31
Director TitleAgeSince
Director/Board Member - 2014-08-31
Director/Board Member 60 2014-11-02
Chairman - 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.87%+3.05%-29.29%-98.59% 2.23M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+2.51%+49.34%+93.39% 65.4B
-1.03%+0.46%+8.14%-5.28% 28.28B
-2.41%-2.95%-9.77%+455.82% 27.16B
-0.20%-1.08%+62.53%+11.49% 26.57B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.37%+1.21%+36.55%-15.78% 20.09B
-2.00%-4.55%+13.11%+530.06% 15.87B
-1.50%+2.92%+43.50%+151.30% 13.9B
Average -0.42%+1.84%+50.46%+164.64% 28.83B
Weighted average by Cap. +0.63%+0.94%+56.37%+155.42%

Financials

2024 2025
Net sales - -
Net income -7.75M -815K -699K -655K -600K -1.13M -77.81M -1.13M -3.03M -39.22M -3.06M -2.99M -130M -4.65M -489K -420K -393K -360K -678K -46.69M -680K -1.82M -23.53M -1.84M -1.8M -77.88M
Net Debt -878K -92.26K -79.2K -74.15K -67.89K -128K -8.81M -128K -343K -4.44M -346K -339K -14.7M -3.14M -330K -284K -265K -243K -458K -31.54M -459K -1.23M -15.9M -1.24M -1.21M -52.62M
Logo Gabather AB
Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s disease.
Employees
2
Date Price Change Volume
26-08-27 SEK 0.0338 -2.87% 5,594,904
26-08-26 SEK 0.0348 +12.99% 3,176,265
26-08-25 SEK 0.0308 0.00% 111,677
26-08-24 SEK 0.0308 -3.75% 1,906,007
26-08-21 SEK 0.0320 +1.27% 343,710
  1. Stock Market
  2. Stocks
  3. GABA Stock